New approaches to treating inflammation
Parent Project Muscular Dystrophy welcomes Dr. Michael Jirousek from Catabasis as our guest for a webinar on June 6, 2012 at 1pm eastern.*
- Topic: New approaches to treating inflammation in Duchenne
- When: Wednesday, June 6, 1pm eastern
Inflammation is a key pathway in the disease pathway in Duchenne’s muscular dystrophy. CAT-1004 is a novel, anti-inflammatory agent being developed by Catabasis as a potential treatment for patients with Duchenne. This presentation will describe the science and rationale behind the development program.
* Unfortunately we will not be able to record this webinar. Catabasis will also be presenting at the 2012 Connect Conference in Ft. Lauderdale, FL.